CD4 and breast carcinoma: For example, a recent report described how an increase in so-called “chronically-stimulated” CD25−CD127− CD4+ T-cells, but not conventional naïve (CD45RO−RA+CD27+CCR7+), effector (CD45RO+RA±CD27−CCR7−), or memory (CD45RO+RA−CD27+CCR7+) CD4+ T-cells, correlated with the regression of breast cancer during neoadjuvant chemotherapy [27].